Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026| Synox | Website
DUBLIN, IRELAND and OXFORD, UK, April 14, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of … Continue reading "SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)"| Synox | Website
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise| Synox | Website
Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team … Continue reading "SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer"| Synox | Website
Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT … Continue reading "SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial"| Synox | Website
SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody Provides flexible loan facility to support additional … Continue reading "SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab"| Synox | Website
TGCT is a debilitating disease that often impacts patients in the prime of their life Designation to include both localized … Continue reading "Emactuzumab designated as an Orphan Medicinal Product in Europe"| Synox | Website
Axel Mescheder, CMO, to present an update on phase III, registrational trial of emactuzumab for patients suffering with TGCT (TANGENT) … Continue reading "SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting"| Synox | Website
Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT) Follows recent appointments of … Continue reading "SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer"| Synox | Website
Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures | Synox | Website